EUVIMEDEUVIMED entdecken
Crossref

IGSF8 is an innate immune checkpoint and cancer immunotherapy target

Yulong Li, Xiangyang Wu, Caibin Sheng, Hailing Liu, Huizhu Liu, Yixuan Tang, Chao Liu, Qingyang Ding, Bin Xie, Xi Xiao, Rongbin Zheng, Quan Yu und 18 weitere

Cell · 2024-05 · 187 (11) · 2703-2716.e23

DOI: 10.1016/j.cell.2024.03.039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2024-05. Verfasst von Yulong Li und 29 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Xunbaihui Biotechnology Co., Ltd., 3rd floor of Building 4, No. 3728, Jinke Road, Pudong New Area, Shanghai, 201203, China. Hauptthemen laut MEDLINE: Immunity, Innate, Immunotherapy, Killer Cells, Natural, Neoplasms. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 85 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune evasion and resistance to cancer immunotherapy, whereas how tumors evade innate immunity is less clear. Using CRISPR screens, we discovered that IGSF8 expressed on tumors suppresses NK cell function by interacting with human KIR3DL2 and mouse Klra9 receptors on NK cells. IGSF8 is normally expressed in neuronal tissues and is not required for cell survival in vitro or in vivo. It is overexpressed and associated with low antigen presentation, low immune infiltration, and worse clinical outcomes in many tumors. An antibody that blocks IGSF8-NK receptor interaction enhances NK cell killing of malignant cells in vitro and upregulates antigen presentation, NK cell-mediated cytotoxicity, and T cell signaling in vivo. In syngeneic tumor models, anti-IGSF8 alone, or in combination with anti-PD1, inhibits tumor growth. Our results indicate that IGSF8 is an innate immune checkpoint that could be exploited as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunity, InnateImmunotherapyKiller Cells, NaturalNeoplasmsAnimalsFemaleHumansMiceAntigen PresentationCell Line, TumorMembrane ProteinsMice, Inbred C57BLAntigens, CDCarrier Proteins

Substanzen

Membrane ProteinsIGSF8 protein, humanAntigens, CDIgSF8 protein, mouseCarrier Proteins

Autor:innen und Institutionen

  • Shanghai Xunbaihui Biotechnology Co., Ltd., 3rd floor of Building 4, No. 3728, Jinke Road, Pudong New Area, Shanghai, 201203, China.
  • GV20 Therapeutics LLC, 237 Putnam Avenue, Cambridge, MA 02139, USA.
  • GV20 Therapeutics LLC, 237 Putnam Avenue, Cambridge, MA 02139, USA. Electronic address: xihao_hu@gv20tx.com.
  • GV20 Therapeutics LLC, 237 Putnam Avenue, Cambridge, MA 02139, USA. Electronic address: xsliu@gv20tx.com.
  • Shanghai Xunbaihui Biotechnology Co., Ltd., 3rd floor of Building 4, No. 3728, Jinke Road, Pudong New Area, Shanghai, 201203, China. Electronic address: tengfei_xiao@gv20tx.com.

Zitieren

APA

Li, Y., Wu, X., Sheng, C., Liu, H., Liu, H., Tang, Y., Liu, C., Ding, Q., Xie, B., Xiao, X., Zheng, R., Yu, Q., Guo, Z., Ma, J., Wang, J., Gao, J., Tian, M., Wang, W., Zhou, J., …, & Xiao, T. (2024). IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell, 187(11), 2703-2716.e23. https://doi.org/10.1016/j.cell.2024.03.039

Vancouver

Li Y, Wu X, Sheng C, Liu H, Liu H, Tang Y, et al. IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell. 2024;187(11):2703-2716.e23. doi:10.1016/j.cell.2024.03.039

BibTeX
@article{Li2024,
  author = {Li, Yulong and Wu, Xiangyang and Sheng, Caibin and Liu, Hailing and Liu, Huizhu and Tang, Yixuan and Liu, Chao and Ding, Qingyang and Xie, Bin and Xiao, Xi and Zheng, Rongbin and Yu, Quan and Guo, Zengdan and Ma, Jian and Wang, Jin and Gao, Jinghong and Tian, Mei and Wang, Wei and Zhou, Jia and Jiang, Li and Gu, Mengmeng and Shi, Sailing and Paull, Michael and Yang, Guanhua and Yang, Wei and Landau, Steve and Bao, Xingfeng and Hu, Xihao and Liu, X Shirley and Xiao, Tengfei},
  title = {IGSF8 is an innate immune checkpoint and cancer immunotherapy target},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {11},
  pages = {2703--2716.e23},
  doi = {10.1016/j.cell.2024.03.039}
}
Kostenlos starten →